Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Ovarian Neoplasms 3Breast Neoplasms 3Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Platinum-resistant Recurrent Ovarian Cancer 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 37Cytarabine 27Methotrexate 22Dexamethasone 20Vincristine 19fludarabine 15Mercaptopurine 14Etoposide 14Radiotherapy 12Daunorubicin 12Asparaginase 12Doxorubicin 11Prednisolone 9Idarubicin 9Busulfan 8pegaspargase 7blinatumomab 7Peripheral Blood Stem Cell Transplantation 6Melphalan 6Immunotherapy, Adoptive 6Imatinib Mesylate 6Dasatinib 6fludarabine phosphate 5Prednisone 5Methylprednisolone 5Filgrastim 5Whole-Body Irradiation 4Thioguanine 4Rituximab 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Precursor Cell Lymphoblastic Leukemia-Lymphoma × 1-dodecylpyridoxal × Clear all
NCT03419494 2018-02-05

Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown
40 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡